A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Verastem, Inc.
Servier
Pfizer
Eli Lilly and Company
Pfizer
Merck Sharp & Dohme LLC
Novartis
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Bristol-Myers Squibb
Pfizer
Seagen Inc.
Fate Therapeutics
Tianjin Medical University Cancer Institute and Hospital
Alterome Therapeutics, Inc.
Novartis
Revolution Medicines, Inc.
Hoffmann-La Roche
University of Chicago
Revolution Medicines, Inc.
Erasca, Inc.
Erasca, Inc.
Eastern Cooperative Oncology Group
Incyte Corporation
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
AstraZeneca
Incyte Corporation
Multitude Therapeutics Inc.
Pfizer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Tizona Therapeutics, Inc
Genentech, Inc.
Memorial Sloan Kettering Cancer Center
Institut du Cancer de Montpellier - Val d'Aurelle
University of Wisconsin, Madison
University of Campania Luigi Vanvitelli
Revolution Medicines, Inc.
Gruppo Oncologico Italia Meridionale
M.D. Anderson Cancer Center
Gruppo Oncologico del Nord-Ovest
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Gruppo Oncologico del Nord-Ovest
M.D. Anderson Cancer Center